More recently, a new class of medicines has been authorised for the management of obesity, the glucagon-like peptide-1 (GLP-1) receptor agonists (tirzepatide, semaglutide, liraglutide) (23). Here, GLP1R is linked to obesity due to melanocortin 4 receptor deficiency.